Sushma Kumar

771 total citations
13 papers, 311 citations indexed

About

Sushma Kumar is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, Sushma Kumar has authored 13 papers receiving a total of 311 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Infectious Diseases, 12 papers in Virology and 2 papers in Epidemiology. Recurrent topics in Sushma Kumar's work include HIV Research and Treatment (12 papers), HIV/AIDS drug development and treatment (12 papers) and HIV/AIDS Research and Interventions (7 papers). Sushma Kumar is often cited by papers focused on HIV Research and Treatment (12 papers), HIV/AIDS drug development and treatment (12 papers) and HIV/AIDS Research and Interventions (7 papers). Sushma Kumar collaborates with scholars based in United States, United Kingdom and France. Sushma Kumar's co-authors include Carey Hwang, Jean‐Michel Molina, George J. Hanna, Peter Sklar, Chloe Orkin, Elizabeth A. Martin, Paul E. Sax, Kathleen Squires, Otto Sussmann and Gina Lin and has published in prestigious journals such as Clinical Infectious Diseases, AIDS and JAIDS Journal of Acquired Immune Deficiency Syndromes.

In The Last Decade

Sushma Kumar

13 papers receiving 308 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sushma Kumar United States 9 284 202 92 80 25 13 311
Luminita Schneider France 12 231 0.8× 259 1.3× 125 1.4× 92 1.1× 19 0.8× 20 355
Juan Tiraboschi Spain 13 312 1.1× 244 1.2× 81 0.9× 108 1.4× 27 1.1× 51 382
Fiona Bisshop Australia 7 259 0.9× 193 1.0× 48 0.5× 92 1.1× 40 1.6× 17 327
David Shamblaw United States 6 341 1.2× 239 1.2× 48 0.5× 143 1.8× 14 0.6× 7 379
Romina Quercia United Kingdom 10 408 1.4× 335 1.7× 75 0.8× 114 1.4× 66 2.6× 16 491
Elisabet Deig Spain 6 120 0.4× 126 0.6× 57 0.6× 117 1.5× 27 1.1× 12 258
Philip Lackey United States 4 397 1.4× 298 1.5× 60 0.7× 171 2.1× 8 0.3× 10 441
Carlos Fernando de Oliveira United States 6 242 0.9× 196 1.0× 54 0.6× 56 0.7× 16 0.6× 7 264
Anita Scribner United States 6 203 0.7× 156 0.8× 48 0.5× 62 0.8× 7 0.3× 7 245
Saadia Mokhtari France 8 205 0.7× 107 0.5× 46 0.5× 124 1.6× 68 2.7× 17 300

Countries citing papers authored by Sushma Kumar

Since Specialization
Citations

This map shows the geographic impact of Sushma Kumar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sushma Kumar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sushma Kumar more than expected).

Fields of papers citing papers by Sushma Kumar

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sushma Kumar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sushma Kumar. The network helps show where Sushma Kumar may publish in the future.

Co-authorship network of co-authors of Sushma Kumar

This figure shows the co-authorship network connecting the top 25 collaborators of Sushma Kumar. A scholar is included among the top collaborators of Sushma Kumar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sushma Kumar. Sushma Kumar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
Maas, Brian M., Julie Strizki, Randy R. Miller, et al.. (2024). Molnupiravir: Mechanism of action, clinical, and translational science. Clinical and Translational Science. 17(2). e13732–e13732. 13 indexed citations
2.
Nelson, Mark, Alan Winston, Andrew Hill, et al.. (2020). Efficacy, safety and central nervous system effects after switch from efavirenz/tenofovir/emtricitabine to doravirine/tenofovir/lamivudine. AIDS. 35(5). 759–767. 7 indexed citations
3.
4.
Martin, Elizabeth A., Ming‐Tain Lai, Winnie Ngo, et al.. (2020). Review of Doravirine Resistance Patterns Identified in Participants During Clinical Development. JAIDS Journal of Acquired Immune Deficiency Syndromes. 85(5). 635–642. 22 indexed citations
5.
Thompson, Melanie, Chloe Orkin, Jean‐Michel Molina, et al.. (2019). Once-daily Doravirine for Initial Treatment of Adults Living With Human Immunodeficiency Virus–1: An Integrated Safety Analysis. Clinical Infectious Diseases. 70(7). 1336–1343. 10 indexed citations
6.
Johnson, Margaret, Princy Kumar, Jean‐Michel Molina, et al.. (2019). Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial. JAIDS Journal of Acquired Immune Deficiency Syndromes. 81(4). 463–472. 64 indexed citations
7.
Wong, Alexander, Deborah Goldstein, Josep Mallolas, et al.. (2019). Efficacy and Safety of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) in Treatment-Naive Adults With HIV-1 and Transmitted Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutations. JAIDS Journal of Acquired Immune Deficiency Syndromes. 82(4). e47–e49. 18 indexed citations
8.
Orkin, Chloe, Jean‐Michel Molina, Johan Lombaard, et al.. (2019). Once-daily Doravirine in Human Immunodeficiency Virus Type 1–Infected, Antiretroviral-naive Adults: An Integrated Efficacy Analysis. Clinical Infectious Diseases. 70(7). 1344–1352. 8 indexed citations
9.
Kumar, Princy, Margaret Johnson, Jean‐Michel Molina, et al.. (2018). LB2. Switch to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial. Open Forum Infectious Diseases. 5(suppl_1). S759–S760. 4 indexed citations
10.
11.
Thompson, Melanie, Chloe Orkin, Jean‐Michel Molina, et al.. (2018). 543. An Integrated Safety Analysis Comparing Once-Daily Doravirine (DOR) to Darunavir+Ritonavir (DRV+r) and Efavirenz (EFV) in HIV-1-Infected, Antiretroviral Therapy (ART)-Naïve Adults. Open Forum Infectious Diseases. 5(suppl_1). S201–S202. 1 indexed citations
12.
Orkin, Chloe, Kathleen Squires, Jean‐Michel Molina, et al.. (2018). LB1. Doravirine/Lamivudine/Tenofovir DF Continues to Be NonInferior to Efavirenz/Emtricitabine/Tenofovir DF in Treatment-Naïve Adults With HIV-1 Infection: Week 96 Results of the DRIVE-AHEAD Trial. Open Forum Infectious Diseases. 5(suppl_1). S759–S759. 9 indexed citations
13.
McNicholas, Paul M., Regis A. Vilchez, Wayne Greaves, et al.. (2012). Detection of HIV-1 CXCR4 tropism and resistance in treatment experienced subjects receiving CCR5 antagonist—Vicriviroc. Journal of Clinical Virology. 55(2). 134–139. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Luminita Schneider Breakdown of academic impact, for papers by Juan Tiraboschi Breakdown of academic impact, for papers by Fiona Bisshop Breakdown of academic impact, for papers by David Shamblaw Breakdown of academic impact, for papers by Romina Quercia Breakdown of academic impact, for papers by Elisabet Deig Breakdown of academic impact, for papers by Philip Lackey Breakdown of academic impact, for papers by Carlos Fernando de Oliveira Breakdown of academic impact, for papers by Anita Scribner Breakdown of academic impact, for papers by Saadia Mokhtari
Rankless by CCL
2026